青城新药-B(02396)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02396 青城新药-B

已收盘 08-20 15:59:01

5.630

+0.680

+13.74%

最高5.650	最低5.000	成交量12.94万
今开5.000	昨收4.950	日振幅13.13%
总市值6.62亿	流通市值4.67亿	总股本1.18亿
成交额71.34万	换手率0.16%	流通股本8,302万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02396","market":"HK","secType":"STK","nameCN":"青城新药-B","latestPrice":5.63,"timestamp":1787212741783,"preClose":4.95,"halted":0,"volume":129400,"delay":0,"changeRate":0.13737373737373731,"floatShares":83022145,"shares":117657522,"eps":-2.08,"marketStatus":"已收盘","change":0.68,"latestTime":"08-20 15:59:01","open":5,"high":5.65,"low":5,"amount":713422,"amplitude":0.131313,"askPrice":5.63,"askSize":1800,"bidPrice":5.6,"bidSize":21800,"shortable":0,"etf":0,"ttmEps":-2.39,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787275800000},"marketStatusCode":5,"adr":0,"listingDate":1766332800000,"exchange":"SEHK","adjPreClose":4.95,"openAndCloseTimeList":[[1787189400000,1787198400000],[1787202000000,1787212800000]],"volumeRatio":3.478495,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02396","defaultTab":"news","newsList":[{"id":"2659144449","title":"青城新药-B(02396.HK)建议采纳股份奖励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2659144449","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659144449?lang=zh_cn&edition=full","pubTime":"2026-08-14 21:17","pubTimestamp":1786713467,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02396","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100283402","title":"华芢生物-B拟设H股股份奖励计划　授出首批约232.96万股奖励股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1100283402","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100283402?lang=zh_cn&edition=full","pubTime":"2026-08-14 21:15","pubTimestamp":1786713348,"startTime":"0","endTime":"0","summary":"华生物-B8月14日公告，董事会已批准建议采纳H股股份奖励计划，但须待股东于2026年9月4日召开的临时股东大会通过后方可生效。该计划属香港联交所《上市规则》第17章所定义的股份计划，将遵守相关规定。以本公告日已发行117,657,522股计算，上限为11,765,752股H股；其中可授予服务提供者的分项上限为上述规模的20%，即2,353,150股H股。为确定临时股东大会的出席及表决资格，公司股东名册将于2026年9月1日至9月4日暂停办理股份过户登记。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659141128","title":"青城新药-B(02396)拟申请H股全流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2659141128","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659141128?lang=zh_cn&edition=full","pubTime":"2026-08-14 20:48","pubTimestamp":1786711707,"startTime":"0","endTime":"0","summary":"智通财经APP讯，青城新药-B 发布公告，鉴于《指引》，董事会已审议并批准参与股东持有的内资股转换为H股(H股)以及该等H股于联交所主板上市及流通。经取得所有相关批准并遵守所有适用的法律、规则及法规后，21,681,762股内资股将转换为H股，且本公司将向联交所申请该等H股于联交所主板上市及买卖。参与股东已同意授予董事会及其授权人士权力以向中国证监会、联交所及其他相关监管机构申请H股全流通，并负责处理有关H股全流通的事宜。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1480296.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02396","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135950352","title":"华芢生物-B（02396）拟申请未上市股份全流通 合计2,168万股占总股本18.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=1135950352","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135950352?lang=zh_cn&edition=full","pubTime":"2026-08-14 20:40","pubTimestamp":1786711245,"startTime":"0","endTime":"0","summary":"2026年8月14日，华生物-B披露公告称，公司董事会已审议并批准向中国证券监督管理委员会及香港联合交易所有限公司申请，将21,681,762股内资股转换为H股并实现全流通，占公司总股本的18.43%。此次全流通涉及六名参与股东，共计64,105,499股现有股份，占公司总股本54.48%。其中，将转换为H股的具体股数及比例如下：","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659625145","title":"青城新药-B(02396)发布中期业绩 期内亏损1.22亿元 同比增加40.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659625145","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659625145?lang=zh_cn&edition=full","pubTime":"2026-08-14 19:18","pubTimestamp":1786706310,"startTime":"0","endTime":"0","summary":"智通财经APP讯，青城新药-B(02396)发布截至2026年6月30日止6个月的中期业绩，该集团其他收入及收益人民币99.9万元，同比增加59.08%;母公司拥有人应占亏损1.22亿元，同比增加40.65%;每股基本及摊薄亏损1.04元;拟派中期股息每股0.50港元。公告称，其他收入及收益增长主要是由于于2025年12月的全球发售所得款项净额带动银行存款的利息收入上升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1480199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131304218","title":"华芢生物-B（02396）发布2026年中期业绩：研发投入6,127.4万元 净亏损扩大至1.22亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1131304218","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131304218?lang=zh_cn&edition=full","pubTime":"2026-08-14 19:06","pubTimestamp":1786705603,"startTime":"0","endTime":"0","summary":"2026年8月14日，华生物科技（青岛）股份有限公司公告截至2026年6月30日止六个月的未经审计中期业绩。期内公司继续加大研发投入，核心产品临床进展稳步推进，但亏损幅度有所扩大。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104519343","title":"华芢生物-B（02396）拟于8月14日召开董事会审议2026年中期业绩及股息","url":"https://stock-news.laohu8.com/highlight/detail?id=1104519343","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104519343?lang=zh_cn&edition=full","pubTime":"2026-08-04 17:47","pubTimestamp":1785836823,"startTime":"0","endTime":"0","summary":"青城新药生物科技（青岛）股份有限公司8月4日公告，公司董事会拟于2026年8月14日（星期五）召开会议，审议并通过截至2026年6月30日止六个月的中期业绩公告，并讨论是否派发中期股息（如有）及处理其他事项。公司提示，香港交易及结算所有限公司及香港联合交易所有限公司对本公告内容概不负责，也未就内容的准确性或完整性作出任何声明，并明确表示概不承担由此产生或因依赖该内容而造成的任何损失。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167045362","title":"华芢生物-B7月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1167045362","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167045362?lang=zh_cn&edition=full","pubTime":"2026-08-03 21:26","pubTimestamp":1785763591,"startTime":"0","endTime":"0","summary":"华生物-B于2026年8月3日公布2026年7月的股份变动月报。根据公告，截至2026年7月31日，公司注册股本保持在1.18亿元人民币。其中，H股依旧维持83,022,145股数量不变，非上市股份则维持在34,635,377股，两类股份数量均无新增、回购或注销活动。公告显示，当月公司并未产生任何股份增发、回购、转让及换股事宜，也无新授或行使的股份期权及其他激励计划。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653030732","title":"华芢生物更名“青城新药” 去年亏损2.09亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653030732","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653030732?lang=zh_cn&edition=full","pubTime":"2026-07-21 21:52","pubTimestamp":1784641950,"startTime":"0","endTime":"0","summary":"近日，华芢生物（02396.HK）发布公告称，公司中文名称正式变更为“青城新药生物科技（青岛）股份有限公司”。自7月22日起，股份简称也将由“华芢生物-B”变更为“青城新药-B”，英文名称、英文股份简称以及股票代码保持不变，同时将于8月14日启用新网站域名。该公司解释称，原名未能直观体现创新药属性，且“芢”字属于生僻字，在政务公示、投融资检索等场景中存在识别和录入不便。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607213815938840.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607213815938840.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652406337","title":"华芢生物-B(02396)中文名称变更为“青城新药生物科技(青岛)股份有限公司”","url":"https://stock-news.laohu8.com/highlight/detail?id=2652406337","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652406337?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:42","pubTimestamp":1784277760,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华芢生物-B(02396)发布公告，公司中文名称已由“华芢生物科技(青岛)股份有限公司”更改为“青城新药生物科技(青岛)股份有限公司”。公司英文名称保持不变。自2026年7月22日上午九时正起，在联交所买卖股份的中文股份简称将由“华芢生物-B”更改为“青城新药-B”。买卖所用英文股份简称保持不变，仍为“B&K CORP-B”，公司股份代号亦保持不变，仍为“2396”。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","MEDX","SYNB","159837","HBImain","GDOC","XBI","02396","AGNG","BK4581","BK1161","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133871342","title":"华芢生物-B（02396）Pro-101-2治疗糖尿病足溃疡II期临床试验完成全部患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1133871342","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133871342?lang=zh_cn&edition=full","pubTime":"2026-07-13 20:15","pubTimestamp":1783944946,"startTime":"0","endTime":"0","summary":"2026年7月13日，华生物科技（青岛）股份有限公司发布自愿公告，披露公司核心产品之一Pro-101-2用于治疗糖尿病足溃疡的II期临床试验已完成全部患者入组。公司称，此次患者入组完成标志着Pro-101-2在糖尿病足溃疡治疗领域的研发工作取得重要进展。公司同时提醒，根据《香港联合交易所有限公司证券上市规则》第18A.05条，Pro-101-2最终能否成功开发及商业化仍存在不确定性。截至公告日，公司董事会由4名执行董事、2名非执行董事及3名独立非执行董事组成。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651001119","title":"华芢生物-B(02396.HK)：Pro-101-2治疗糖尿病足溃疡的II期临床试验完成全部患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2651001119","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651001119?lang=zh_cn&edition=full","pubTime":"2026-07-13 20:14","pubTimestamp":1783944869,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189716943","title":"华芢生物-B6月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1189716943","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189716943?lang=zh_cn&edition=full","pubTime":"2026-07-03 16:37","pubTimestamp":1783067827,"startTime":"0","endTime":"0","summary":"华生物科技（青岛）股份有限公司于2026年7月3日发布的截至2026年6月30日止2026年6月证券变动月报表显示，公司本月未有新增发行、购回或注销股份，股权结构保持稳定。公司于报告期内未实施任何新股发行、股份购回或出售、转换及库藏股变动；先前采纳的员工激励计划未对公司发行股份构成稀释影响。公司同时确认，截至2026年6月末，相应股份类别符合适用的最低公众持股量要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150593534","title":"华芢生物-B5月股份变动月报表显示股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1150593534","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150593534?lang=zh_cn&edition=full","pubTime":"2026-06-03 18:37","pubTimestamp":1780483039,"startTime":"0","endTime":"0","summary":"华生物科技（青岛）股份有限公司于2026年6月3日发布了截至2026年5月31日的股份变动月报表。公告显示，报告期内公司未新增任何发行、购回或注销股份，股本结构保持稳定。根据公告，华生物-B注册股本合计为人民币117,657,522元。其中，已在香港联合交易所上市的H股数量为83,022,145股，面值为每股人民币1元，非上市股份数量为34,635,377股，面值同为每股人民币1元。两类股份与上月相比均无增减变动。本报告由公司联席公司秘书张丽婷签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634123732","title":"华芢生物-B(02396)：Pro-101-1治疗深二度烧烫伤的IIIa期临床试验完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2634123732","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2634123732?lang=zh_cn&edition=full","pubTime":"2026-05-12 21:16","pubTimestamp":1778591775,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华芢生物-B(02396)发布公告，公司研发并用于治疗深二度烧烫伤的Pro-101-1的IIIa期临床试验，于近日完成了首例患者入组。Pro-101-1为公司核心产品之一。本临床试验为一项随机、双盲、安慰剂对照研究，旨在进一步评价重组人血小板源生长因子(rhPDGF-BB)凝胶治疗深 Ⅱ度烧伤创面的有效性和安全性，并在大量入组受试者中为后续IIIb期临床试验的设计提供关键参数。此次Pro-101-1的IIIa期临床试验完成首例患者入组是公司在烧烫伤治疗领域上的又一次重大的研发进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440889.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110071241","title":"华芢生物-B4月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1110071241","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110071241?lang=zh_cn&edition=full","pubTime":"2026-05-06 17:07","pubTimestamp":1778058459,"startTime":"0","endTime":"0","summary":"华生物科技（青岛）股份有限公司于2026年5月6日发布2026年4月股份变动月报表。报告显示，截至2026年4月30日，华生物-B的各类已发行及注册股本均保持不变，无新增发行、回购或注销行为。报告提及，华生物-B已按照适用的上市规则及相关法律法规进行所有与本月可能发生的证券发行或库藏股相关事项，并得到董事会正式授权。本次公告由华生物-B联席公司秘书张丽婷签署并发布。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195879750","title":"华芢生物-B2025年收入翻倍至5.22亿元 研发投入稳步推进净亏损同比微降","url":"https://stock-news.laohu8.com/highlight/detail?id=1195879750","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195879750?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:10","pubTimestamp":1777461030,"startTime":"0","endTime":"0","summary":"2025年度，华生物-B实现收入5.22亿元人民币，同比增长100%，并超越2023年度的4.72亿元。受益于PDGF类新药销售带动，报告期内公司毛利达4.81亿元，毛利率为92.1%。公司年内除税前亏损2.09亿元，较2024年度的2.12亿元略有收窄，但与2023年度的1.05亿元相比有所扩大。研发支出为0.89亿元，较2024年度的0.91亿元轻微下降2.1%，但较2023年度的0.40亿元增长逾一倍。与此同时，经营活动现金流出规模有所收窄至0.81亿元，主要与报告期内持续加大研发投入以及推进核心管线相关。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华芢生物-B2025年收入翻倍至5.22亿元 研发投入稳步推进净亏损同比微降","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1184901943","title":"华芢生物-B更新3月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1184901943","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184901943?lang=zh_cn&edition=full","pubTime":"2026-04-09 18:51","pubTimestamp":1775731882,"startTime":"0","endTime":"0","summary":"2026年4月9日，华生物科技（青岛）股份有限公司公布截至2026年3月31日的股份变动月报表。根据公告，报告期内公司注册及已发行股本未发生变化。公告显示，公司截至本月末的注册股本合计为117,657,522股。报告期内未有新增发行、购回或注销股份，也无任何库藏股变动。本次月报表由公司联席公司秘书张丽婷呈交。根据公告披露，未来若出现任何股份发行或回购，公司将依法依规及时进行披露。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623234673","title":"华芢生物-B(02396)发布年度业绩，净亏损2.09亿元 同比减少1.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623234673","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2623234673?lang=zh_cn&edition=full","pubTime":"2026-03-30 22:17","pubTimestamp":1774880255,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华芢生物-B(02396)发布截至2025年12月31日止年度业绩，该集团取得收入52.2万元，同比增加100%;年内亏损2.09亿元，同比减少1.5%;每股亏损2.08元。公告称，收入增加乃主要由于向一名单一客户销售用于研究及实验的 PDGF BB试剂，该销售属一次性性质。提供研究服务及销售 PDGF-BB试剂均不属于我们的核心业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422193.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161901468","title":"华芢生物-B 2025业绩：收入翻倍至5.22亿元，核心产品临床进展稳步推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1161901468","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161901468?lang=zh_cn&edition=full","pubTime":"2026-03-30 21:42","pubTimestamp":1774878146,"startTime":"0","endTime":"0","summary":"在截至2025年12月31日止年度，华生物-B实现收入5.22亿元人民币，较2024年的2.61亿元人民币增长100.0%。销售主要来自向单一客户提供一次性性质的PDGF-BB试剂，带动毛利由2024年的2.41亿元人民币增至4.81亿元人民币，毛利率维持在92.1%左右。报告期内，公司亏损2.09亿元人民币，较2024年的2.12亿元人民币收窄1.5%；母公司普通权益持有人应占每股亏损为2.08元人民币。整体而言，报告期内收入增长显著，核心产品临床试验进展稳步，为公司后续研发及市场拓展奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.huarenshengwu.com/en/","stockEarnings":[{"period":"1week","weight":0.3026},{"period":"1month","weight":0.2758},{"period":"3month","weight":-0.0951},{"period":"6month","weight":-0.4695},{"period":"1year","weight":-0.8704},{"period":"ytd","weight":-0.6939}],"compareEarnings":[{"period":"1week","weight":0.0022},{"period":"1month","weight":0.014},{"period":"3month","weight":0.0043},{"period":"6month","weight":-0.0348},{"period":"1year","weight":0.0148},{"period":"ytd","weight":-0.0053}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"华芢生物科技（青岛）股份有限公司是一家主要从事生物制药研发的中国公司。该公司致力于开发疗法，重点是针对有医疗需求及市场机会的适应症开发蛋白质药物。该公司的主攻方向是发现、开发和商业化伤口愈合的疗法，目前为血小板衍生生长因子（PDGF）药物。该公司主要在中国国内市场开展业务。","exchange":"SEHK","name":"青城新药-B","nameEN":"B&K CORP-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"青城新药-B(02396)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供青城新药-B(02396)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"青城新药-B,02396,青城新药-B股票,青城新药-B股票老虎,青城新药-B股票老虎国际,青城新药-B行情,青城新药-B股票行情,青城新药-B股价,青城新药-B股市,青城新药-B股票价格,青城新药-B股票交易,青城新药-B股票购买,青城新药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"青城新药-B(02396)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供青城新药-B(02396)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}